Nymox: Positive Data For Prostate Cancer Drug NX-1207

(RTTNews) - Nymox Pharmaceutical Corp (NYMX) Tuesday reported positive new study findings showing that the company's NX-1207 Phase 2 treatment for localized low-risk prostate cancer did not affect testosterone levels in treated men.

According to the company, analysis of testosterone levels post-treatment for men treated with NX-1207 2.5 mg (n=47) or 15 mg (n=46) showed no statistically significant change as compared to control active surveillance patients (n=48). This data is consistent with the large body of existing data for men treated with NX-1207 (n over 1,000) showing a favorable sexual profile for the treatment.

One of the major problems with current prostate treatments for localized prostate cancer (radical prostatectomy, external beam radiation, or brachytherapy) is the relatively high incidence of reported sexual dysfunction post-treatment. In now 8 completed studies, NX-1207 treatment has shown to have no significant adverse effect post-treatment on sexual function or testosterone levels.

NX-1207 has had an excellent safety profile as both a treatment for benign prostatic hyperplasia (BPH) and localized low-risk prostate cancer.

NX-1207 is in Phase 3 development in the US and Europe for benign prostatic hyperplasia (BPH) also referred to as prostate enlargement, a common affliction of middle-aged and elderly men, affecting up to half of men over the age of 50. The company's European partner for BPH is Recordati S.p.A.